Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

A user humorously shared that someone at their high school gave out finasteride pills, which introduced them to the drug for their receding hairline. The conversation also touched on the high school's location and appearance, with some users joking about their own hair loss and treatments like minoxidil and finasteride.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

The conversation discusses a user's positive experience with hair regrowth using topical finasteride, minoxidil, and microneedling after 2.5 months, noting initial shedding but improved hair density, especially at the temples, possibly eliminating the need for a hair transplant. The user is satisfied with the current treatment and is hesitant to try the experimental drug RU58841, hoping the current routine will suffice for further improvements.

Hair loss treatments are generally categorized as anti-androgens, like finasteride and RU58841, which prevent hair loss by targeting DHT, and growth stimulators, such as minoxidil, rosemary oil, microneedling, and LLLT, which promote hair growth by increasing blood flow and growth factors. The user is seeking to confirm these categories and understand if there are other treatments or mechanisms of action.

This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.

Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Oral treatments for hair loss, like Dutasteride and Minoxidil, may be more effective than topical ones, though topical formulations can be similarly effective except for Minoxidil. Topical treatments can be a chore to apply and are often used as supplements to oral treatments.

A 22-year-old is frustrated with ongoing hair loss despite using treatments like topical minoxidil, finasteride, microneedling, oral dutasteride, and oral minoxidil. Their dermatologist suggests treating scalp inflammation with oral tretinoin and using exosomes for alopecia.

New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The user has been using oral minoxidil and finasteride but has seen no regrowth, only stabilization of hair loss. Suggestions include considering a hair transplant or adding topical treatments, with some users sharing similar experiences of stabilization without regrowth.

Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

Taking a slow and steady approach to treating hair loss, as well as the potential risks of combining too many treatments. The post suggests trialling individual treatments (such as Minoxidil, finasteride, or RU58841) for an extended period before adding more into your treatment protocol.

A 29-year-old male experiencing hair loss due to TRT is using minoxidil and dermarolling but is hesitant to use finasteride or dutasteride due to potential side effects. He is considering low level laser therapy (LLLT), PRP, ketoconazole shampoo, and oral minoxidil as additional treatments. A reply suggests that without a DHT blocker like finasteride or dutasteride, other treatments may not be effective long-term.

Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.

Finasteride, minoxidil, dermarolling, and topical antiandrogens are effective for hair regrowth. Future treatments may include CB0301 and hair cloning.

The individual is considering starting hair loss treatment with dutasteride, prescribed by a dermatologist, due to concerns about finasteride side effects. They are also interested in the potential benefits of reducing DHT and are contemplating whether to maintain a shaved head or pursue treatment.

A user discusses a topical prescription for hair regrowth containing Minoxidil, Finasteride, and Latanoprost, noting Latanoprost's side effect of promoting eyelash and eyebrow growth. Others share experiences and information about Latanoprost, highlighting its origins as a glaucoma drug and potential side effects.

Grapefruit juice doesn't significantly affect finasteride or dutasteride. Drinking topical minoxidil is risky; saw palmetto is less effective than finasteride or dutasteride for hair loss.

25-year-old male with Norwood 2 hair loss tried PRP injections without success. Dermatologists didn't recommend finasteride or minoxidil, but suggested PRP + Mesotherapy for 50% improvement.

A 43-year-old man started treatment for hair loss with finasteride, minoxidil, Qilib rebalance, and Trigain Caffeine shampoo, and is taking vitamin D supplements. He hopes to share positive results after a few months.

A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.